Yuichiro Tada

List of Publications by Year
in descending order

56	1,325	430442	360668
papers	citations	18 h-index	35 g-index

58	58	58	1144
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Salivary Duct Carcinoma. Journal of Clinical Oncology, 2019, 37, 125-134.	0.8	157
2	A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Annals of Oncology, 2018, 29, 979-984.	0.6	146
3	Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. International Journal of Clinical Oncology, 2015, 20, 35-44.	1.0	94
4	Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients. Annals of Surgical Oncology, 2016, 23, 2038-2045.	0.7	80
5	Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget, 2017, 8, 59023-59035.	0.8	79
6	Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. American Journal of Surgical Pathology, 2019, 43, 984-994.	2.1	63
7	Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathology, 2020, 128, 693-703.	1.4	63
8	Facial Nerve Enhancement in Gd-MRI in Patients with Bell's palsy. Acta Oto-Laryngologica, 1994, 114, 165-169.	0.3	45
9	Histopathological evaluation of minor salivary gland papillaryâ€“cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. Histopathology, 2020, 76, 411-422.	1.6	39
10	Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Oncotarget, 2018, 9, 1852-1867.	0.8	39
11	Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Scientific Reports, 2020, 10, 16988.	1.6	32
12	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treatment Reviews, 2020, 89, 102069.	3.4	32
13	Gd-DTPA Enhanced MRI in Ramsay Hunt Syndrome. Acta Oto-Laryngologica, 1994, 114, 170-174.	0.3	28
14	Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Medicine, 2020, 9, 5015-5024.	1.3	28
15	Evolutionary analysis of influenza C virus M genes. Virus Genes, 1997, 15, 53-59.	0.7	27
16	Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. Anticancer Research, 2020, 40, 5277-5283.	0.5	24
17	Classification of tumors by imaging diagnosis and preoperative fineâ€needle aspiration cytology in 120 patients with tumors in the parapharyngeal space. Head and Neck, 2019, 41, 1277-1281.	0.9	23
18	Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan. Oncotarget, 2017, 8, 1083-1091.	0.8	23

#	Article	IF	Citations
19	The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. American Journal of Surgical Pathology, 2021, 45, 885-894.	2.1	21
20	Prognostic impact of CRTC1/3â€MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study. Cancer Science, 2020, 111, 4195-4204.	1.7	20
21	Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. In Vivo, 2019, 33, 843-853.	0.6	19
22	The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan. International Journal of Clinical Oncology, 2020, 25, 1774-1785.	1.0	19
23	Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system. Cancer Science, 2021, 112, 1184-1195.	1.7	19
24	Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma. Oncotarget, 2018, 9, 17043-17055.	0.8	17
25	Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers, 2020, 12, 3427.	1.7	17
26	Phosphorylation of influenza C virus CM2 protein. Virus Research, 1998, 58, 65-72.	1.1	15
27	A multiâ€institutional study of salivary gland cytopathology: Application of the Milan System for Reporting Salivary Gland Cytopathology in Japan. Cancer Cytopathology, 2022, 130, 30-40.	1.4	14
28	Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3â€MAML2 fusions, and clinicopathological features. Histopathology, 2022, 80, 729-735.	1.6	14
29	Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3â€“MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology, 2020, 76, 1013-1022.	1.6	11
30	Central pathology review of salivary gland adenoid cystic carcinoma. Head and Neck, 2020, 42, 1721-1727.	0.9	11
31	Sebaceous Carcinoma of the Parotid Gland. Clinical Nuclear Medicine, 2010, 35, 260-262.	0.7	10
32	Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2020, 44, 526-535.	2.1	10
33	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. Cancers, 2021, 13, 3527.	1.7	10
34	The high expression of <scp>FOXA</scp>1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases. Histopathology, 2018, 73, 943-952.	1.6	9
35	Sialadenoma Papilliferum of the Bronchus. American Journal of Surgical Pathology, 2021, 45, 662-671.	2.1	9
36	Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3â€MAML2 fusions. Head and Neck, 2018, 40, 2565-2573.	0.9	8

#	Article	IF	Citations
37	Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo, 2020, 34, 2653-2657.	0.6	7
38	The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 291-299.	1.4	7
39	The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. Frontiers in Oncology, 2021, 11, 779882.	1.3	7
40	Efficacy and safety of a vessel sealing system in oral cancer resection and reconstructive surgery. Acta Oto-Laryngologica, 2018, 138, 759-762.	0.3	6
41	Resection of Parapharyngeal Space Tumors Located in the Prestyloid Compartment: Efficacy of the Cervical Approach. Annals of Surgical Oncology, 2021, 28, 3066-3072.	0.7	6
42	Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy. International Cancer Conference Journal, 2016, 5, 150-153.	0.2	4
43	Venous malformation of the parapharyngeal space: Two surgical case reports and a literature review. Otolaryngology Case Reports, 2019, 13, 100130.	0.0	3
44	Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncology Letters, 2012, 4, 898-904.	0.8	1
45	A clinical analysis of 45 operation cases of pleomorphic adenoma occurred in parapharyngeal space. Journal of Japan Society for Head and Neck Surgery, 2017, 27, 53-59.	0.0	1
46	A study of 12 cases of submandibular gland carcinoma. Journal of Japan Society for Head and Neck Surgery, 2017, 27, 67-72.	0.0	1
47	Novel approach for unresectable salivary duct carcinoma: Targeting HER2 and androgen receptor.. Journal of Clinical Oncology, 2018, 36, 6084-6084.	0.8	1
48	Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. Anticancer Research, 2022, 42, 1607-1613.	0.5	1
49	Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).. Journal of Clinical Oncology, 2022, 40, 6079-6079.	0.8	1
50	A novel technique of arterial blood flow modification in intra-arterial chemoradiotherapy of maxillary sinus squamous cell carcinoma. Oral Oncology, 2020, 109, 104873.	0.8	0
51	An attempt at scoring laryngeal findings for cannula replacement after head and neck cancer reconstructive surgery. Japanese Journal of Head and Neck Cancer, 2019, 45, 310-313.	0.0	0
52	What is the best way of resection for subtotal glossectomy?. Journal of Japanese Society of Oral Oncology, 2019, 31, 181-189.	0.0	0
53	A Case of Cervical Lymph Node Metastasis from a p16-Positive Unknown Primary Cancer Diagnosed by Needle Biopsy. Practica Otologica, 2020, 113, 569-573.	0.0	0
54	ADC histogram analysis of MR imaging in the different diagnosis between benign and malignant tumors in the parapharyngeal space. Japanese Journal of Head and Neck Cancer, 2020, 46, 248-253.	0.0	0

#	Article	IF	Citations
55	How to dissect the para-hyoid lymph nodes for tongue cancer. Japanese Journal of Head and Neck Cancer, 2022, 48, 14-20.	0.0	0
56	A Study of Laryngectomy with Hyoid Bone Preservation Performed at Our Center. Journal of Japan Society for Head and Neck Surgery, 2022, 32, 1-7.	0.0	0